UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

A review of trabectedin (ET-743): a unique mechanism of action

Molecular cancer therapeutics, 2010-08, Vol.9 (8), p.2157-2163

2010

Volltextzugriff (PDF)

Metformin Suppresses Tumor Progression by Inactivating Stromal Fibroblasts in Ovarian Cancer

Molecular cancer therapeutics, 2018-06, Vol.17 (6), p.1291-1302

2018

Volltextzugriff (PDF)

Mechanisms of Resistance to NTRK Inhibitors and Therapeutic Strategies in NTRK1-Rearranged Cancers

Molecular cancer therapeutics, 2017-10, Vol.16 (10), p.2130-2143

2017

Volltextzugriff (PDF)

Activation of IL-6R/JAK1/STAT3 signaling induces de novo resistance to irreversible EGFR inhibitors in non-small cell lung cancer with T790M resistance mutation

Molecular cancer therapeutics, 2012-10, Vol.11 (10), p.2254-2264

2012

Volltextzugriff (PDF)

MET activation mediates resistance to lapatinib inhibition of HER2-amplified gastric cancer cells

Molecular cancer therapeutics, 2012-03, Vol.11 (3), p.660-669

2012

Volltextzugriff (PDF)

Resistance to RET-Inhibition in RET-Rearranged NSCLC Is Mediated By Reactivation of RAS/MAPK Signaling

Molecular cancer therapeutics, 2017-08, Vol.16 (8), p.1623-1633

2017

Volltextzugriff (PDF)

Expression of ABCG2 (BCRP) is regulated by Nrf2 in cancer cells that confers side population and chemoresistance phenotype

Molecular cancer therapeutics, 2010-08, Vol.9 (8), p.2365-2376

2010

Volltextzugriff (PDF)

The Slow Cycling Phenotype: A Growing Problem for Treatment Resistance in Melanoma

Molecular cancer therapeutics, 2017-06, Vol.16 (6), p.1002-1009

2017

Volltextzugriff (PDF)

Sunitinib dose escalation overcomes transient resistance in clear cell renal cell carcinoma and is associated with epigenetic modifications

Molecular cancer therapeutics, 2015-02, Vol.14 (2), p.513-522

2015

Volltextzugriff (PDF)

Resistance Mechanism against Trastuzumab in HER2-Positive Cancer Cells and Its Negation by Src Inhibition

Molecular cancer therapeutics, 2017-06, Vol.16 (6), p.1145-1154

2017

Volltextzugriff (PDF)

Discovery of a Novel ATP-Competitive MEK Inhibitor DS03090629 that Overcomes Resistance Conferred by BRAF Overexpression in BRAF-Mutated Melanoma

Molecular cancer therapeutics, 2023-03, Vol.22 (3), p.317-332

2023

Volltextzugriff (PDF)

KDM6B Counteracts EZH2-Mediated Suppression of IGFBP5 to Confer Resistance to PI3K/AKT Inhibitor Treatment in Breast Cancer

Molecular cancer therapeutics, 2018-09, Vol.17 (9), p.1973-1983

2018

Volltextzugriff (PDF)

Potential advantages of CUDC-101, a multitargeted HDAC, EGFR, and HER2 inhibitor, in treating drug resistance and preventing cancer cell migration and invasion

Molecular cancer therapeutics, 2013-06, Vol.12 (6), p.925-936

2013

Volltextzugriff (PDF)

An In Vivo Functional Screen Identifies JNK Signaling As a Modulator of Chemotherapeutic Response in Breast Cancer

Molecular cancer therapeutics, 2017-09, Vol.16 (9), p.1967-1978

2017

Volltextzugriff (PDF)

Inhibition of ABCB1 Overcomes Cancer Stem Cell-like Properties and Acquired Resistance to MET Inhibitors in Non-Small Cell Lung Cancer

Molecular cancer therapeutics, 2015-11, Vol.14 (11), p.2433-2440

2015

Volltextzugriff (PDF)

Identification and Validation of Compounds Selectively Killing Resistant Cancer: Delineating Cell Line-Specific Effects from P-Glycoprotein-Induced Toxicity

Molecular cancer therapeutics, 2017-01, Vol.16 (1), p.45-56

2017

Volltextzugriff (PDF)

Inhibition of Mer and Axl receptor tyrosine kinases in astrocytoma cells leads to increased apoptosis and improved chemosensitivity

Molecular cancer therapeutics, 2010-05, Vol.9 (5), p.1298-1307

2010

Volltextzugriff (PDF)

Aberrant Expression of ERG Promotes Resistance to Combined PI3K and AR Pathway Inhibition through Maintenance of AR Target Genes

Molecular cancer therapeutics, 2019-09, Vol.18 (9), p.1577-1586

2019

Volltextzugriff (PDF)

MEK Inhibition Overcomes Cisplatin Resistance Conferred by SOS/MAPK Pathway Activation in Squamous Cell Carcinoma

Molecular cancer therapeutics, 2015-07, Vol.14 (7), p.1750-1760

2015

Volltextzugriff (PDF)

Pharmacological and Structural Characterizations of Naquotinib, a Novel Third-Generation EGFR Tyrosine Kinase Inhibitor, in EGFR -Mutated Non-Small Cell Lung Cancer

Molecular cancer therapeutics, 2018-04, Vol.17 (4), p.740-750

2018

Volltextzugriff (PDF)

Cosilencing of PKM-2 and MDR-1 Sensitizes Multidrug-Resistant Ovarian Cancer Cells to Paclitaxel in a Murine Model of Ovarian Cancer

Molecular cancer therapeutics, 2015-07, Vol.14 (7), p.1521-1531

2015

Volltextzugriff (PDF)

Mechanistic basis for overcoming platinum resistance using copper chelating agents

Molecular cancer therapeutics, 2012-11, Vol.11 (11), p.2483-2494

2012

Volltextzugriff (PDF)

Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib

Molecular cancer therapeutics, 2014-02, Vol.13 (2), p.353-363

2014

Volltextzugriff (PDF)

The relationship of thioredoxin-1 and cisplatin resistance: its impact on ROS and oxidative metabolism in lung cancer cells

Molecular cancer therapeutics, 2012-03, Vol.11 (3), p.604-615

2012

Volltextzugriff (PDF)

Small-molecule IAP antagonists sensitize cancer cells to TRAIL-induced apoptosis: roles of XIAP and cIAPs

Molecular cancer therapeutics, 2014-01, Vol.13 (1), p.5-15

2014

Volltextzugriff (PDF)

1 – 25 von 816

Suche als RSS-Feed

Aktive Filter

KollektionSpringerLINK Contemporary (Konsortium Baden-Württemberg)

ThemaDrug Resistance

Zeitschrift / SerieMolecular Cancer Therapeutics

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(816)
Mit Volltextzugriff
(809)

Publikationsform

Artikel
(816)

Sprache

Englisch
(816)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Humans
(797)
Oncology
(757)
Life Sciences & Biomedicine
(754)
Science & Technology
(754)
Cell Line, Tumor
(558)
Animals
(418)
Mice
(336)
Drug Resistance, Neoplasm
(317)
Antineoplastic Agents - Pharmacology
(299)
Female
(291)
Drug Resistance, Neoplasm - Genetics
(288)
Xenograft Model Antitumor Assays
(264)
Drug Resistance, Neoplasm - Drug Effects
(254)
Apoptosis - Drug Effects
(190)
Cell Proliferation - Drug Effects
(180)
Protein Kinase Inhibitors - Pharmacology
(147)
Gene Expression Regulation, Neoplastic - Drug Effects
(145)
Male
(126)
Signal Transduction - Drug Effects
(123)
Cell Survival - Drug Effects
(119)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

EZB Electronic Journals Library
(816)
MEDLINE
(815)

Zeitschrift / Serie

Mol. Cancer Ther
(1)

Menü

Weitere Dienste

Einstellungen

A review of trabectedin (ET-743): a unique mechanism of action

Metformin Suppresses Tumor Progression by Inactivating Stromal Fibroblasts in Ovarian Cancer

Mechanisms of Resistance to NTRK Inhibitors and Therapeutic Strategies in NTRK1-Rearranged Cancers

Activation of IL-6R/JAK1/STAT3 signaling induces de novo resistance to irreversible EGFR inhibitors in non-small cell lung cancer with T790M resistance mutation

MET activation mediates resistance to lapatinib inhibition of HER2-amplified gastric cancer cells

Resistance to RET-Inhibition in RET-Rearranged NSCLC Is Mediated By Reactivation of RAS/MAPK Signaling

Expression of ABCG2 (BCRP) is regulated by Nrf2 in cancer cells that confers side population and chemoresistance phenotype

The Slow Cycling Phenotype: A Growing Problem for Treatment Resistance in Melanoma

Sunitinib dose escalation overcomes transient resistance in clear cell renal cell carcinoma and is associated with epigenetic modifications

Resistance Mechanism against Trastuzumab in HER2-Positive Cancer Cells and Its Negation by Src Inhibition

Discovery of a Novel ATP-Competitive MEK Inhibitor DS03090629 that Overcomes Resistance Conferred by BRAF Overexpression in BRAF-Mutated Melanoma

KDM6B Counteracts EZH2-Mediated Suppression of IGFBP5 to Confer Resistance to PI3K/AKT Inhibitor Treatment in Breast Cancer

Potential advantages of CUDC-101, a multitargeted HDAC, EGFR, and HER2 inhibitor, in treating drug resistance and preventing cancer cell migration and invasion

An In Vivo Functional Screen Identifies JNK Signaling As a Modulator of Chemotherapeutic Response in Breast Cancer

Inhibition of ABCB1 Overcomes Cancer Stem Cell-like Properties and Acquired Resistance to MET Inhibitors in Non-Small Cell Lung Cancer

Identification and Validation of Compounds Selectively Killing Resistant Cancer: Delineating Cell Line-Specific Effects from P-Glycoprotein-Induced Toxicity

Inhibition of Mer and Axl receptor tyrosine kinases in astrocytoma cells leads to increased apoptosis and improved chemosensitivity

Aberrant Expression of ERG Promotes Resistance to Combined PI3K and AR Pathway Inhibition through Maintenance of AR Target Genes

MEK Inhibition Overcomes Cisplatin Resistance Conferred by SOS/MAPK Pathway Activation in Squamous Cell Carcinoma

Pharmacological and Structural Characterizations of Naquotinib, a Novel Third-Generation EGFR Tyrosine Kinase Inhibitor, in EGFR -Mutated Non-Small Cell Lung Cancer

Cosilencing of PKM-2 and MDR-1 Sensitizes Multidrug-Resistant Ovarian Cancer Cells to Paclitaxel in a Murine Model of Ovarian Cancer

Mechanistic basis for overcoming platinum resistance using copper chelating agents

Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib

The relationship of thioredoxin-1 and cisplatin resistance: its impact on ROS and oxidative metabolism in lung cancer cells

Small-molecule IAP antagonists sensitize cancer cells to TRAIL-induced apoptosis: roles of XIAP and cIAPs

Aktive Filter

Suchergebnisse filtern